Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Cidara Therapeutics, Inc. (CDTX) has a Wall Street consensus price target of $177.88, based on estimates from 11 covering analysts. With the stock currently trading at $221.38, this represents a potential downside of -19.6%. The company has a market capitalization of $6.96B.
Analyst price targets range from a low of $150.00 to a high of $221.50, representing a 40% spread in expectations. The median target of $170.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CDTX trades at a trailing P/E of -8.3x. Analysts expect EPS to grow +47.5% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CDTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonCDTX's consensus price target is $177.88, -19.6% below the current price of $221.38. The 11 analysts tracking CDTX see downside risk at present valuations.
CDTX has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $177.88 implies -19.6% downside from current levels.
CDTX's current price is $221.38 with a consensus target of $177.88 (-19.6% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $221.5 for CDTX, while the most conservative target is $150. The consensus of $177.88 represents the median expectation. These targets typically reflect 12-month expectations.
CDTX is moderately covered, with 11 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 7 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CDTX stock forecast based on 11 Wall Street analysts shows a consensus price target of $177.88, with estimates ranging from $150 (bear case) to $221.5 (bull case). The median consensus rating is "Buy".
Analysts are cautious on CDTX, with 0 Sell ratings and a price target of $177.88 (-19.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CDTX analyst price targets range from $150 to $221.5, a 40% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $177.88 consensus represents the middle ground.